Sarcoplasmic MxA expression has been shown to be a DM hallmark, and the European NeuroMuscular Center (ENMC) 2018 DM classification criteria include perifascicular MxA overexpression as definite DM muscle biopsy findings (26). This evidence concerns the gene MX1 and dermatomyositis.